Formulations comprising hydrocortisone are disclosed in a suppository for methods of treating ulcerative colitis and other gastrointestinal diseases and disorders. Administering a single hydrocortisone suppository once a day achieves remission or reduction of a symptom, optionally followed by a period of time in which the dosage is reduced.
Formulations comprising hydrocortisone are disclosed in a suppository for methods of treating ulcerative colitis and other gastrointestinal diseases and disorders. Administering a single hydrocortisone suppository once a day achieves remission or reduction of a symptom, optionally followed by a period of time in which the dosage is reduced.
A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Suppositories being pharmaceutical preparations for the treatment of Ulcerative Colitis; Pharmaceutical preparations for the treatment of Ulcerative Colitis Medical apparatus for introducing pharmaceutical preparations into the human body
Formulations comprising hydrocortisone are disclosed in a suppository for methods of treating ulcerative colitis and other gastrointestinal diseases and disorders. Administering a single hydrocortisone suppository once a day achieves remission or reduction of a symptom, optionally followed by a period of time in which the dosage is reduced.
A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
7.
SUPPOSITORY INSERTION DEVICE, SUPPOSITORY, AND METHOD OF MANUFACTURING A SUPPOSITORY
Today's suppositories are typically packaged individually for digital administration into the anal canal of a patient. A suppository applicator described herein, which works with individually packaged suppositories, can alternatively be shipped in a prepackaged operational arrangement with a suppository to enable the patient to administer the suppository through use of the applicator in a single operation after opening a hygienic wrapper containing the applicator-suppository combination. A method for manufacturing a suppository includes manufacturing the suppository in the presence of and in contact with an element configured to be used to insert the suppository into a body cavity. The method may include using the element to define a shape of the suppository during the manufacturing. The resulting applicator-suppository combination is more hygienic and easier to handle than the separate applicator and suppository and provides more efficiency from time of opening the packaging to time of commencing administration of the suppository
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
A45D 40/00 - Casings or accessories specially adapted for storing or handling solid or pasty toiletry or cosmetic substances, e.g. shaving soaps or lipsticks
A45D 40/08 - Casings or accessories specially adapted for storing or handling solid or pasty toiletry or cosmetic substances, e.g. shaving soaps or lipsticks with provision for sieves or shaping parts for stick ends
A45D 40/12 - Casings with provision for preventing undesired movement of the stick
A45D 40/16 - Refill sticksMoulding devices for producing sticks
A45D 40/20 - Pencil-like cosmeticsSimple holders for handling stick-shaped cosmetics or shaving soap while in use
A61B 50/30 - Containers specially adapted for packaging, protecting, dispensing, collecting or disposing of surgical or diagnostic appliances or instruments
A61J 3/08 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of suppositories or sticks
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
8.
SUPPOSITORY INSERTION DEVICE, SUPPOSITORY, AND METHOD OF MANUFACTURING A SUPPOSITORY
Today's suppositories are typically packaged individually for digital administration into the anal canal of a patient. A suppository applicator described herein, which works with individually packaged suppositories, can alternatively be shipped in a prepackaged operational arrangement with a suppository to enable the patient to administer the suppository through use of the applicator in a single operation after opening a hygienic wrapper containing the applicator-suppository combination. A method for manufacturing a suppository includes manufacturing the suppository in the presence of and in contact with an element configured to be used to insert the suppository into a body cavity. The method may include using the element to define a shape of the suppository during the manufacturing. The resulting applicator-suppository combination is more hygienic and easier to handle than the separate applicator and suppository and provides more efficiency from time of opening the packaging to time of commencing administration of the suppository
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
A45D 40/00 - Casings or accessories specially adapted for storing or handling solid or pasty toiletry or cosmetic substances, e.g. shaving soaps or lipsticks
A45D 40/08 - Casings or accessories specially adapted for storing or handling solid or pasty toiletry or cosmetic substances, e.g. shaving soaps or lipsticks with provision for sieves or shaping parts for stick ends
A45D 40/12 - Casings with provision for preventing undesired movement of the stick
A45D 40/16 - Refill sticksMoulding devices for producing sticks
A45D 40/20 - Pencil-like cosmeticsSimple holders for handling stick-shaped cosmetics or shaving soap while in use
A61B 50/30 - Containers specially adapted for packaging, protecting, dispensing, collecting or disposing of surgical or diagnostic appliances or instruments
A61J 3/08 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of suppositories or sticks
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
9.
DEVELOPMENT AND VALIDATION OF THE HEMORRHOID DISEASE SYMPTOM IMPACT MEASURE
Disclosed is a method of assessing health of a patient that includes presenting a patient reported outcome measure (PROM) for at least partial completion by the patient about an illness, injury, or condition. The PROM including questions extending beyond a question about a symptom or sign of the illness, injury, or condition. The method further includes performing a calculation as a function of responses to the questions to assess the health of the patient. A particular embodiment includes correlating a result of the calculation with an objective measurement of the symptom or sign to produce patient reported outcome information for assessing the health of the patient.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
10.
SINGLE-USE SUPPOSITORY INSERTION DEVICE AND METHOD
A single-use suppository insertion device includes a barrel, a plunger configured to be movably coupled to the barrel, and a disabling feature of the barrel or the plunger. The disabling feature may be configured to be activated during operational motion of the plunger relative to the barrel, such as during insertion of or withdrawal away from a suppository. The device can include a structural element of the barrel or the plunger configured to engage with the disabling feature of the barrel or the plunger during insertion of or withdrawal away from the suppository to activate the disabling feature. The disabling feature may be implemented in a number of ways to ensure single-use operation of the single-use suppository insertion device.
The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.
A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
12.
DEVELOPMENT AND VALIDATION OF THE HEMORRHOID DISEASE SYMPTOM IMPACT MEASURE
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
13.
DEVELOPMENT AND VALIDATION OF THE HEMORRHOID DISEASE SYMPTOM IMPACT MEASURE
Disclosed is a method of assessing health of a patient that includes presenting a patient reported outcome measure (PROM) for at least partial completion by the patient about an illness, injury, or condition. The PROM including questions extending beyond a question about a symptom or sign of the illness, injury, or condition. The method further includes performing a calculation as a function of responses to the questions to assess the health of the patient. A particular embodiment includes correlating a result of the calculation with an objective measurement of the symptom or sign to produce patient reported outcome information for assessing the health of the patient.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
A61B 5/02 - Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
14.
Hydrocortisone acetate suppository formulation for treatment of disease
The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.
A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
15.
Hydrocortisone acetate suppository formulation for treatment of disease
The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.
A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
16.
Hydrocortisone acetate suppository formulation for treatment of disease
The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.
A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
17.
Hydrocortisone acetate suppository formulation for treatment of disease
The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.
A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
18.
Hydrocortisone acetate suppository formulation for treatment of disease
The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.
A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Providing a medical condition assessment system in the nature of questionnaires to be completed by patients with the results to be used by patients and healthcare professionals for assessing current medical conditions of patients and changes in the conditions
21.
Single-use suppository insertion device and method
A single-use suppository insertion device includes a barrel, a plunger configured to be movably coupled to the barrel, and a disabling feature of the barrel or the plunger. The disabling feature may be configured to be activated during operational motion of the plunger relative to the barrel, such as during insertion of or withdrawal away from a suppository. The device can include a structural element of the barrel or the plunger configured to engage with the disabling feature of the barrel or the plunger during insertion of or withdrawal away from the suppository to activate the disabling feature. The disabling feature may be implemented in a number of ways to ensure single-use operation of the single-use suppository insertion device.
The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.
A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
23.
Suppository insertion device, suppository, and method of manufacturing a suppository
Today's suppositories are typically packaged individually for digital administration into the anal canal of a patient. A suppository applicator described herein, which works with individually packaged suppositories, can alternatively be shipped in a prepackaged operational arrangement with a suppository to enable the patient to administer the suppository through use of the applicator in a single operation after opening a hygienic wrapper containing the applicator-suppository combination. A method for manufacturing a suppository includes manufacturing the suppository in the presence of and in contact with an element configured to be used to insert the suppository into a body cavity. The method may include using the element to define a shape of the suppository during the manufacturing. The resulting applicator-suppository combination is more hygienic and easier to handle than the separate applicator and suppository and provides more efficiency from time of opening the packaging to time of commencing administration of the suppository.
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
A45D 40/16 - Refill sticksMoulding devices for producing sticks
A61B 50/30 - Containers specially adapted for packaging, protecting, dispensing, collecting or disposing of surgical or diagnostic appliances or instruments
A61J 3/08 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of suppositories or sticks
A45D 40/00 - Casings or accessories specially adapted for storing or handling solid or pasty toiletry or cosmetic substances, e.g. shaving soaps or lipsticks
A45D 40/08 - Casings or accessories specially adapted for storing or handling solid or pasty toiletry or cosmetic substances, e.g. shaving soaps or lipsticks with provision for sieves or shaping parts for stick ends
A45D 40/12 - Casings with provision for preventing undesired movement of the stick
A45D 40/20 - Pencil-like cosmeticsSimple holders for handling stick-shaped cosmetics or shaving soap while in use
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
24.
Hydrocortisone acetate suppository formulation for treatment of disease
The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
(1) Medical apparatus for introducing pharmaceutical preparations into the human body, namely injection syringes, vaginal syringes, injection instruments without needles, injection needles.
Today's suppositories are typically packaged individually for digital administration into the anal canal of a patient. A suppository applicator described herein, which works with individually packaged suppositories, can alternatively be shipped in a prepackaged operational arrangement with a suppository to enable the patient to administer the suppository through use of the applicator in a single operation after opening a hygienic wrapper containing the applicator-suppository combination. A method for manufacturing a suppository includes manufacturing the suppository in the presence of and in contact with an element configured to be used to insert the suppository into a body cavity. The method may include using the element to define a shape of the suppository during the manufacturing. The resulting applicator-suppository combination is more hygienic and easier to handle than the separate applicator and suppository and provides more efficiency from time of opening the packaging to time of commencing administration of the suppository.
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
A61J 3/08 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of suppositories or sticks
A61B 50/30 - Containers specially adapted for packaging, protecting, dispensing, collecting or disposing of surgical or diagnostic appliances or instruments
A45D 40/16 - Refill sticksMoulding devices for producing sticks
A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
A61K 9/00 - Medicinal preparations characterised by special physical form
A45D 40/00 - Casings or accessories specially adapted for storing or handling solid or pasty toiletry or cosmetic substances, e.g. shaving soaps or lipsticks
A45D 40/08 - Casings or accessories specially adapted for storing or handling solid or pasty toiletry or cosmetic substances, e.g. shaving soaps or lipsticks with provision for sieves or shaping parts for stick ends
A45D 40/12 - Casings with provision for preventing undesired movement of the stick
A45D 40/20 - Pencil-like cosmeticsSimple holders for handling stick-shaped cosmetics or shaving soap while in use
28.
Single-use suppository insertion device and method
A single-use suppository insertion device includes a barrel, a plunger to be movably coupled to the barrel, and a disabling feature of the barrel or the plunger. The disabling feature may be activated during operational motion of the plunger relative to the barrel, such as during insertion of or withdrawal away from a suppository. The device can include a structural element of the barrel or the plunger to engage with the disabling feature of the barrel or the plunger during insertion of or withdrawal away from the suppository to activate the disabling feature. The disabling feature may be implemented in a number of ways to ensure single-use operation of the single-use suppository insertion device.
The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
31.
SINGLE-USE SUPPOSITORY INSERTION DEVICE AND METHOD
A single-use suppository insertion device (100) includes a barrel (110), a plunger (115) configured to be movably coupled to the barrel, and a disabling feature (131) of the barrel or the plunger. The disabling feature may be configured to be activated during operational motion of the plunger relative to the barrel, such as during insertion of or withdrawal away from a suppository. The device can include a structural element of the barrel or the plunger configured to engage with the disabling feature of the barrel or the plunger during insertion of or withdrawal away from the suppository to activate the disabling feature. The disabling feature may be implemented in a number of ways to ensure single-use operation of the single-use suppository insertion device.
A single-use suppository insertion device (100) includes a barrel (110), a plunger (115) configured to be movably coupled to the barrel, and a disabling feature (131) of the barrel or the plunger. The disabling feature may be configured to be activated during operational motion of the plunger relative to the barrel, such as during insertion of or withdrawal away from a suppository. The device can include a structural element of the barrel or the plunger configured to engage with the disabling feature of the barrel or the plunger during insertion of or withdrawal away from the suppository to activate the disabling feature. The disabling feature may be implemented in a number of ways to ensure single-use operation of the single-use suppository insertion device.
Rectal suppositories are used to administer a predetermined drug dosage to treat a variety of diseases and symptoms in a variety of patient populations. Certain medical conditions, such as digestive disorders, may be more effectively treated when the suppository is placed in a particular location of the patient's anal canal or rectum. An apparatus for inserting a suppository can include an applicator having a barrel, such as a hollow cylindrical body, and a plunger, such as a substantially cylindrical elongated body. The apparatus can include features to ensure that beneficial gas flow paths associated with the plunger or the barrel are maintained or that the apparatus can accommodate suppositories of different sizes. Embodiments may include features to facilitate gripping and manipulation of the apparatus for use by patients with limited dexterity. These benefits may encourage patients to maintain a course of treatment, thereby potentially avoiding additional complications, hospitalization, and costs.
The present disclosure relates, in various embodiments, to a drug delivery element comprising a component having a first shape external from a rectum and configured to form a second shape internal to the rectum, the second shape having a configuration to expose a drug to tissues of the rectum. In additional embodiments, the drug delivery element can comprise a shell defining an internal cavity configured to contain an active drug ingredient in a stable form and wherein the shell is further configured to release the active drug ingredient following placement into a rectum. The drug delivery element can be useful for administration of hydrocortisone, e.g., hydrocortisone acetate, to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
37.
HYDROCORTISONE ACETATE SUPPOSITORY FORMULATION FOR TREATMENT OF DISEASE
The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
38.
HYDROCORTISONE ACETATE SUPPOSITORY FORMULATION FOR TREATMENT OF DISEASE
The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.
A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
Today's suppositories are typically packaged individually for digital administration into the anal canal of a patient. A suppository applicator described herein, which works with individually packaged suppositories, can alternatively be shipped in a prepackaged operational arrangement with a suppository to enable the patient to administer the suppository through use of the applicator in a single operation after opening a hygienic wrapper containing the applicator-suppository combination. A method for manufacturing a suppository includes manufacturing the suppository in the presence of and in contact with an element configured to be used to insert the suppository into a body cavity. The method may include using the element to define a shape of the suppository during the manufacturing. The resulting applicator-suppository combination is more hygienic and easier to handle than the separate applicator and suppository and provides more efficiency from time of opening the packaging to time of commencing administration of the suppository.
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
A61J 3/08 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of suppositories or sticks
A61B 50/30 - Containers specially adapted for packaging, protecting, dispensing, collecting or disposing of surgical or diagnostic appliances or instruments
A45D 40/16 - Refill sticksMoulding devices for producing sticks
A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
A61K 9/00 - Medicinal preparations characterised by special physical form
A45D 40/00 - Casings or accessories specially adapted for storing or handling solid or pasty toiletry or cosmetic substances, e.g. shaving soaps or lipsticks
A45D 40/08 - Casings or accessories specially adapted for storing or handling solid or pasty toiletry or cosmetic substances, e.g. shaving soaps or lipsticks with provision for sieves or shaping parts for stick ends
A45D 40/12 - Casings with provision for preventing undesired movement of the stick
A45D 40/20 - Pencil-like cosmeticsSimple holders for handling stick-shaped cosmetics or shaving soap while in use
Today's suppositories are typically packaged individually for digital administration into the anal canal of a patient. A suppository applicator described herein, which works with individually packaged suppositories, can alternatively be shipped in a prepackaged operational arrangement with a suppository to enable the patient to administer the suppository through use of the applicator in a single operation after opening a hygienic wrapper containing the applicator-suppository combination. A method for manufacturing a suppository includes manufacturing the suppository in the presence of and in contact with an element configured to be used to insert the suppository into a body cavity. The method may include using the element to define a shape of the suppository during the manufacturing. The resulting applicator-suppository combination is more hygienic and easier to handle than the separate applicator and suppository and provides more efficiency from time of opening the packaging to time of commencing administration of the suppository.
A61J 3/08 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of suppositories or sticks
A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
44.
Method and apparatus for inserting a rectal suppository
Rectal suppositories are used to administer a predetermined drug dosage to treat a variety of diseases and symptoms in a variety of patient populations. Certain medical conditions, such as digestive disorders, may be more effectively treated when the suppository is placed in a particular location of the patient's anal canal or rectum. An apparatus for inserting a suppository can include an applicator having a barrel, such as a hollow cylindrical body, and a plunger, such as a substantially cylindrical elongated body. The apparatus can include features to ensure that beneficial gas flow paths associated with the plunger or the barrel are maintained or that the apparatus can accommodate suppositories of different sizes. Embodiments may include features to facilitate gripping and manipulation of the apparatus for use by patients with limited dexterity. These benefits may encourage patients to maintain a course of treatment, thereby potentially avoiding additional complications, hospitalization, and costs.
Rectal suppositories are used to administer a predetermined drug dosage to treat a variety of diseases and symptoms in a variety of patient populations. Certain medical conditions, such as digestive disorders, may be more effectively treated when the suppository is placed in a particular location of the patient's anal canal or rectum. A method and apparatus for inserting a suppository into an animal or human may include an applicator having a barrel and plunger. The barrel maintains a first gas flow path during insertion of a suppository and the plunger maintains a second gas flow path during withdrawal of the plunger. By maintaining the first and second gas flow paths, trapped air and suction effects on the suppository are minimized or eliminated. Furthermore, patients may immediately resume day-to-day activities. These benefits may encourage patients to maintain a course of treatment thereby potentially avoiding additional complications, hospitalization, and costs.
Rectal suppositories are used to administer a predeter-mined drug dosage to treat a variety of diseases and symptoms in a vari-ety of patient populations. Certain medical conditions, such as digestive disorders, may be more effectively treated when the suppository is placed in a particular location of the patient's anal canal or rectum. A method and apparatus for inserting a suppository into an animal or hu-man may include an applicator having a barrel and plunger. The barrel maintains a first gas flow path during insertion of a suppository and the plunger maintains a second gas flow path during withdrawal of the plunger. By maintaining a first and second gas flow path, trapped air and suction effects on the suppository are minimized or eliminated. Further-more, patients may immediately resume day-today activities. These ben-efits may encourage patients to maintain a course of treatment thereby potentially avoiding additional complications, hospitalization, and costs.
Rectal suppositories are used to administer a predetermined drug dosage to treat a variety of diseases and symptoms in a variety of patient populations. Certain medical conditions, such as digestive disorders, may be more effectively treated when the suppository is placed in a particular location of the patient's anal canal or rectum. A method and apparatus for inserting a suppository into an animal or human may include an applicator having a barrel and plunger. The barrel maintains a first gas flow path during insertion of a suppository and the plunger maintains a second gas flow path during withdrawal of the plunger. By maintaining a first and second gas flow path, trapped air and suction effects on the suppository are minimized or eliminated. Furthermore, patients may immediately resume day-to-day activities. These benefits may encourage patients to maintain a course of treatment thereby potentially avoiding additional complications, hospitalization, and costs.
